Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 206.00
+2.00 (0.98%)
Last updated: Apr 17, 2026, 8:00 PM CET
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
€605,662
Profits / Employee
€191,786
Market Cap
12.18B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Jan 1, 2023 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Ascendis Pharma News
- 2 days ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire
- 3 days ago - Ascendis Pharma (ASND) Begins Trading on Nasdaq Global Select Market - GuruFocus
- 3 days ago - Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq - GlobeNewsWire
- 15 days ago - Ascendis Pharma (ASND) Shifts to Nasdaq Direct Listing - GuruFocus
- 15 days ago - Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewsWire
- 15 days ago - ASND: Promising Results from Ascendis Pharma's TransCon Therapies in Achondroplasia - GuruFocus
- 15 days ago - New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia - GlobeNewsWire
- 16 days ago - FDA Grants Orphan Drug Exclusivity To Ascendis Pharma's YUVIWEL In Achondroplasia - Nasdaq